Venturing into the Brave New World of Diagnostics Start-Ups

Few diagnostics start-ups are {bona fide} business successes, and that has put a damper on venture capital interest in the field. But this hasn't stopped start-ups trying to meet needs in cancer diagnostics, sample preparation and point-of-care.

Few diagnostics start-ups are bona fidebusiness successes, and that has put a damper on venture capital interest in the field. But it hasn't stopped some hearty pioneers from making bets on diagnostic tests. Perhaps they are attracted by the shorter time-to-market for diagnostics than pharmaceuticals or biotechnology, or the promise of a technology that meets an unmet need. Then again, diagnostics IPOs seem to garner attractive step-up multiples; a 5.2 pre-money average in 1997 and post-money average of 8.4, better than pharmaceutical companies' post-IPO multiple of 3.14 and 5.0 for device IPOs (including financings through August of ‘97), regardless of their eventual business success.(Step-up multiples calculate the increase in value from one financing round to the next by dividing pre-and post-money IPO valuations by total private investment.)

If investor interest is low, it isn't because the world has all the diagnostic tests it needs. And it isn't...

More from R&D

More from Scrip

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By 

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.